Cfi is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cfi is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The CFI gene encodes complement factor I, a serine protease that plays a critical role in regulating all three complement pathways. Factor I cleaves and inactivates C3b and C4b, requiring cofactors for its activity. The gene is located on chromosome 4p25.3 and encodes a protein of 406 amino acids [1].
Factor I is a member of the serine protease family and circulates in plasma at low concentrations (~35 μg/mL). It is synthesized primarily in the liver but is also expressed in various tissues including the brain. The protein consists of a heavy chain (containing the protease domain) and a light chain (containing the cofactor domains) held together by a disulfide bond [2].
Function
Function
Factor I is the only known protease that can cleave C3b and C4b, but requires cofactor proteins for its activity:
C3b Cleavage: Factor I cleaves C3b at specific sites, generating inactive C3b (iC3b)
Requires cofactors: CFH, MCP (CD46), C4BP, CR1
Cleavage sites: Arg1281, Arg1298, Arg1299
C4b Cleavage: Factor I inactivates C4b
Requires cofactors: C4BP, CR1
Generates C4c and C4d fragments
Limited C5 Cleavage: Factor I can also cleave C5 (limited activity)
Does not generate functional C5a
May regulate terminal pathway activation
Biological Importance
Controls amplification of all complement pathways
Prevents immune complex deposition
Protects host tissues from complement-mediated damage
Essential for immune homeostasis
Disease Associations
Alzheimer's Disease
CFI variants have been implicated in AD risk in genome-wide studies
Altered CFI levels observed in AD cerebrospinal fluid
CFI may interact with complement activation in AD neuroinflammation
The role of CFI in amyloid clearance is under investigation [3]
Age-Related Macular Degeneration
CFI variants are associated with AMD risk, particularly in European populations [4]
The study of Cfi has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.